IL288104B1 - Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer - Google Patents
Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancerInfo
- Publication number
- IL288104B1 IL288104B1 IL288104A IL28810421A IL288104B1 IL 288104 B1 IL288104 B1 IL 288104B1 IL 288104 A IL288104 A IL 288104A IL 28810421 A IL28810421 A IL 28810421A IL 288104 B1 IL288104 B1 IL 288104B1
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- pharmaceutical compositions
- heterocyclic compounds
- heterocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019087772 | 2019-05-21 | ||
| CN2019095947 | 2019-07-15 | ||
| CN2019123223 | 2019-12-05 | ||
| PCT/CN2020/091274 WO2020233592A1 (en) | 2019-05-21 | 2020-05-20 | Heterocyclic compounds, preparation methods and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL288104A IL288104A (en) | 2022-01-01 |
| IL288104B1 true IL288104B1 (en) | 2026-04-01 |
Family
ID=73459463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288104A IL288104B1 (en) | 2019-05-21 | 2020-05-20 | Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11091481B2 (enExample) |
| EP (1) | EP3972967A4 (enExample) |
| JP (2) | JP7100210B2 (enExample) |
| KR (1) | KR102944305B1 (enExample) |
| CN (3) | CN114437065A (enExample) |
| AU (1) | AU2020279287B2 (enExample) |
| BR (1) | BR112021023136A2 (enExample) |
| CA (1) | CA3139348A1 (enExample) |
| IL (1) | IL288104B1 (enExample) |
| MX (1) | MX2021014096A (enExample) |
| WO (1) | WO2020233592A1 (enExample) |
| ZA (1) | ZA202110422B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| ES3004338T3 (en) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Combination therapies |
| KR102871791B1 (ko) | 2018-09-10 | 2025-10-15 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| TWI831855B (zh) | 2018-10-26 | 2024-02-11 | 日商大鵬藥品工業股份有限公司 | 新穎吲唑化合物或其鹽 |
| CA3112129A1 (en) | 2018-12-05 | 2020-06-11 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| CA3148745A1 (en) | 2019-08-29 | 2021-03-04 | Xiaolun Wang | Kras g12d inhibitors |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| WO2021106230A1 (ja) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | 新規なフェノール化合物又はその塩 |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| KR20220130126A (ko) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | Sos1 억제제 |
| CN113105448A (zh) * | 2020-01-13 | 2021-07-13 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| EP4092026A4 (en) * | 2020-01-13 | 2024-03-06 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF |
| CN112159405B (zh) * | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | 吡啶并嘧啶酮类化合物及其应用 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN114901663B (zh) * | 2020-03-02 | 2024-07-02 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
| CN114075195B (zh) * | 2020-08-21 | 2026-04-28 | 广东东阳光药业股份有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| US12286431B2 (en) | 2020-09-11 | 2025-04-29 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| CN116390919B (zh) * | 2020-11-24 | 2025-12-23 | 杭州多域生物技术有限公司 | 一种芳香化合物、其制备方法及应用 |
| CA3200164A1 (en) * | 2020-11-26 | 2022-06-02 | Qingxin Liu | Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| KR20230088804A (ko) * | 2020-12-21 | 2023-06-20 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | 마크로시클릭 k-ras g12c 억제제, 이의 제조 방법 및 용도 |
| US20240189313A1 (en) * | 2021-03-11 | 2024-06-13 | InventisBio Co., Ltd. | Solid dispersions |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| EP4395769A1 (en) | 2021-09-01 | 2024-07-10 | Novartis AG | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023190748A1 (ja) | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN117462553A (zh) * | 2022-07-20 | 2024-01-30 | 益方生物科技(上海)股份有限公司 | 药物组合产品以及组合疗法 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CN120813358A (zh) | 2023-04-06 | 2025-10-17 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327380A (en) | 2023-09-29 | 2026-05-01 | D3 Bio Wuxi Co Ltd | Combinations of WX-001 or its derivatives with KRAS G12C inhibitor for use in cancer treatment |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025242126A1 (zh) * | 2024-05-22 | 2025-11-27 | 上海正大天晴医药科技开发有限公司 | 一种药物组合及其应用 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119183A2 (en) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019051291A1 (en) * | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108658972A (zh) | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种取代内酰胺类化合物及其制备方法和用途 |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| CA3100390A1 (en) * | 2018-06-12 | 2020-03-12 | Amgen Inc. | Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer |
| ES3004042T3 (en) | 2018-11-09 | 2025-03-11 | Hoffmann La Roche | Fused ring compounds |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CN110256421A (zh) | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| CN111377918B (zh) | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | 一种kras抑制剂化合物 |
| CN111205286B (zh) | 2020-01-13 | 2022-12-13 | 中科苏州药物研究院 | 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用 |
-
2020
- 2020-05-20 CN CN202210122162.7A patent/CN114437065A/zh active Pending
- 2020-05-20 EP EP20810834.0A patent/EP3972967A4/en active Pending
- 2020-05-20 KR KR1020217041335A patent/KR102944305B1/ko active Active
- 2020-05-20 IL IL288104A patent/IL288104B1/en unknown
- 2020-05-20 JP JP2021569009A patent/JP7100210B2/ja active Active
- 2020-05-20 MX MX2021014096A patent/MX2021014096A/es unknown
- 2020-05-20 AU AU2020279287A patent/AU2020279287B2/en active Active
- 2020-05-20 CA CA3139348A patent/CA3139348A1/en active Pending
- 2020-05-20 BR BR112021023136A patent/BR112021023136A2/pt unknown
- 2020-05-20 CN CN202080004519.0A patent/CN112585129B/zh active Active
- 2020-05-20 CN CN202410157715.1A patent/CN118359609A/zh active Pending
- 2020-05-20 WO PCT/CN2020/091274 patent/WO2020233592A1/en not_active Ceased
-
2021
- 2021-02-10 US US17/172,988 patent/US11091481B2/en active Active
- 2021-07-01 US US17/365,503 patent/US12110289B2/en active Active
- 2021-12-14 ZA ZA2021/10422A patent/ZA202110422B/en unknown
-
2022
- 2022-06-30 JP JP2022105508A patent/JP7679338B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119183A2 (en) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2019051291A1 (en) * | 2017-09-08 | 2019-03-14 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3972967A4 (en) | 2023-07-12 |
| ZA202110422B (en) | 2024-03-27 |
| CN112585129A (zh) | 2021-03-30 |
| JP7679338B2 (ja) | 2025-05-19 |
| KR102944305B1 (ko) | 2026-03-25 |
| EP3972967A1 (en) | 2022-03-30 |
| US12110289B2 (en) | 2024-10-08 |
| IL288104A (en) | 2022-01-01 |
| JP7100210B2 (ja) | 2022-07-12 |
| MX2021014096A (es) | 2022-02-11 |
| AU2020279287A1 (en) | 2021-12-16 |
| US20210355125A1 (en) | 2021-11-18 |
| BR112021023136A2 (pt) | 2022-01-04 |
| AU2020279287B2 (en) | 2025-11-27 |
| CN114437065A (zh) | 2022-05-06 |
| WO2020233592A1 (en) | 2020-11-26 |
| JP2022525247A (ja) | 2022-05-11 |
| CN112585129B (zh) | 2022-03-01 |
| US11091481B2 (en) | 2021-08-17 |
| CA3139348A1 (en) | 2020-11-26 |
| KR20220010542A (ko) | 2022-01-25 |
| US20210198255A1 (en) | 2021-07-01 |
| JP2022130631A (ja) | 2022-09-06 |
| CN118359609A (zh) | 2024-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
| IL314347A (en) | Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| IL291388A (en) | Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment or alleviation of cancer | |
| IL276290A (en) | Heteroaryl compounds, their pharmaceutical preparations and their medical use | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| SI3759083T1 (sl) | Derivati 2,4-diaminokinazolina in njihova uporaba v zdravljenju virusnih okužb, raka ali alergij | |
| CA3292080A1 (en) | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | |
| IL274008A (en) | Anti-MSLN antibody and a pharmaceutical preparation containing it for the treatment of cancer | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| IL271013B (en) | Allosteric egfr inhibitors with a modified isoindole, pharmaceutical preparations containing them and their use in medical treatment and/or preventive treatment of cancer | |
| IL307402A (en) | The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| IL284980B1 (en) | Heteroaryl-azacyclic-oxo-amide compound, pharmaceutical preparation and pharmaceutical preparation for use in the treatment | |
| PL3937948T3 (pl) | Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych | |
| SG11202103806VA (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| PL3768246T3 (pl) | Kompozycje farmaceutyczne sapozyny c i ich zastosowanie w leczeniu nowotworu | |
| HUE053866T2 (hu) | Gyógyászati készítmény székrekedés kezelésére |